The Effect of Continuous Care Model On the Bone Marrow Transplantation Complications

Phase 3

• Conditions: Condition 1: aplastic anaemia. Condition 2: Multiple myeloma. Condition 3: Hodgkin lymphoma. Condition 4: non-Hodgkin lymphoma. Condition 5: Lymphoblastic leukemia. Condition 6: Myeloblastic leukemia.; Other aplastic anaemias; Multiple myeloma; Hodgkin lymphoma; Other and unspecified types of non-Hodgkin lymphoma; Lymphoid leukaemia; Myeloid leukaemia

• Registration Number: IRCT20170923036337N2
• Lead Sponsor: Vice chancellor for research of Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 March 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

Have at least reading and writing skills,
Age between 15 and 60 years,
Lack of verbal and perceptual and psychological disorders
The patient should not be simultaneously in another study

Exclusion Criteria

The patient is a member of the treatment team,
Incidence of intense complications after bone marrow transplantation
Relapse of disease
Death of Patient

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Graft-Versus-Host Disease (GVHD). Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: GVHD grading using the Glucksberg grade scale.;Oral mucositis. Timepoint: Before Stem Cell Transplantation and every 4 weeks for the first 3 months after transplantation. Method of measurement: WHO Oral Mucositis Grading Scale.;The rate of re-admission related to stem cell transplantation. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: the number of days that patient admit in the post-transplant stem cell care unit.;Signs and symptoms of infection. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: Clinical examination and symptom registration.;Anxiety. Timepoint: Before Stem Cell Transplantation and every 4 weeks for the first 3 months after transplantation. Method of measurement: The State-Trait Anxiety Inventory and VAS Tool.